Drug Price Trends for NDC 70121-1467

Average Pharmacy Cost for 70121-1467

Drug Name	NDC	Price/Unit ($)	Unit	Date
MEDROXYPROGESTERONE 150 MG/ML	70121-1467-05	19.76327	ML	2026-03-18
MEDROXYPROGESTERONE 150 MG/ML	70121-1467-02	20.26495	ML	2026-03-18
MEDROXYPROGESTERONE 150 MG/ML	70121-1467-05	20.27834	ML	2026-02-18
MEDROXYPROGESTERONE 150 MG/ML	70121-1467-02	20.92247	ML	2026-02-18
MEDROXYPROGESTERONE 150 MG/ML	70121-1467-05	20.50396	ML	2026-01-21

Best Wholesale Price for NDC 70121-1467

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
MEDROXYPROGESTERONE ACETATE 150MG/ML INJ,SUSP	AvKare, LLC	70121-1467-02	1ML	13.97	13.97000	2024-01-10 - 2028-06-14	FSS

Dupixent (Dupilumab) Market Dynamics and Price Projections

Last updated: February 19, 2026

Dupixent (dupilumab), a monoclonal antibody targeting the interleukin-4 receptor alpha subunit, has established a significant market presence across multiple inflammatory conditions. Its efficacy in atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) underpins current market valuation and future growth. The drug's mechanism of action, inhibiting key inflammatory pathways, allows for broad application, driving prescription volumes and revenue.

What is Dupixent's Current Market Penetration and Approved Indications?

Dupixent (NDC: 70121-1467) has secured broad market penetration due to its approval for a growing list of inflammatory diseases. Initial approvals focused on moderate-to-severe atopic dermatitis in adults and adolescents, where it demonstrated superior efficacy compared to topical corticosteroids and other systemic agents [1]. This was followed by approvals for moderate-to-severe pediatric atopic dermatitis, indicating expanding patient eligibility.

The drug's utility broadened significantly with its indication for moderate-to-severe eosinophilic asthma and oral corticosteroid-dependent asthma [2]. This expansion targets a large patient population with unmet needs, where biologic therapies offer a distinct advantage in managing airway inflammation.

Further market expansion occurred with the approval for CRSwNP in adult patients who are not adequately controlled with nasal corticosteroids [3]. This indication leverages Dupixent's anti-inflammatory properties in a different anatomical site, addressing chronic sinus issues. Recent approvals for prurigo nodularis in adults and adolescents also represent a new therapeutic area, highlighting the drug's versatility [4].

The diverse approved indications have been critical to Dupixent's commercial success. These approvals have been supported by robust clinical trial data demonstrating significant improvement in disease control, reduction in exacerbations, and enhanced quality of life for patients across these conditions.

How do Dupixent's Efficacy and Safety Profiles Impact Market Position?

Dupixent's market position is strongly correlated with its consistent efficacy and favorable safety profile across its approved indications. Clinical studies have consistently shown significant reductions in disease severity scores, such as the Eczema Area and Severity Index (EASI) for atopic dermatitis, and a decrease in asthma exacerbation rates [1, 2]. For CRSwNP, studies report marked improvement in nasal polyp size and sense of smell [3].

Compared to existing treatments, Dupixent offers a distinct advantage. In atopic dermatitis, it provides a non-steroidal systemic option that is generally well-tolerated, unlike many oral immunosuppressants with systemic side effects [1]. In asthma, it offers an alternative to oral corticosteroids, which are associated with significant long-term toxicity [2]. This targeted mechanism of action, focusing on specific inflammatory pathways, results in a generally lower incidence of the broad systemic side effects seen with corticosteroids or broad immunosuppressants.

The safety profile is characterized by common adverse events that are typically manageable, including injection site reactions, conjunctivitis, and nasopharyngitis [1, 2, 3]. While conjunctivitis requires monitoring, it is generally reversible and less debilitating than the underlying inflammatory conditions. The overall safety record supports long-term treatment adherence, a crucial factor for chronic diseases. This established efficacy and safety translate into high physician confidence and patient preference, reinforcing its market leadership.

What is the Competitive Landscape for Dupixent?

The competitive landscape for Dupixent varies by indication.

Atopic Dermatitis: Dupixent faces competition from JAK inhibitors (e.g., abrocitinib, upadacitinib) and other biologics targeting different pathways, such as IL-13 inhibitors (e.g., lebrikizumab, tralokinumab) [5]. While JAK inhibitors offer oral administration and rapid onset, they carry a different safety profile, including a boxed warning for serious infections, thrombosis, and malignancy [6]. Tralokinumab, another IL-4 receptor antagonist, offers a similar mechanism but has shown varying efficacy data compared to Dupixent in head-to-head comparisons or analyses of trial outcomes [7]. Lebrikizinab is a direct IL-13 inhibitor that has also demonstrated efficacy.

Asthma: In severe asthma, Dupixent competes with other biologics targeting different mechanisms, including anti-IgE therapy (omalizumab), anti-IL-5 therapies (mepolizumab, reslizumab, benralizumab), and IL-33 inhibitors (tezepelumab) [8]. Tezepelumab, targeting upstream IL-33, has shown broad efficacy across different asthma phenotypes, representing a significant competitive threat [9].

CRSwNP: Competition in CRSwNP is less developed, with Dupixent being a leading biologic option [3]. However, other biologics approved for asthma may find off-label use or future approval in this space.

Prurigo Nodularis: This is a newer indication with less established biologic competition, positioning Dupixent with a first-mover advantage in this specific segment [4].

The primary competitive advantage for Dupixent remains its established efficacy and safety across multiple indications, coupled with a broad label and a substantial body of real-world evidence supporting its use. However, newer entrants with novel mechanisms or improved administration routes pose increasing challenges.

What are the Key Patent Expirations and Generic Entry Timelines?

Dupixent's patent portfolio is complex, with multiple patents covering the composition of matter, manufacturing processes, and methods of use. The key patents are nearing expiration.

The primary composition of matter patent for dupilumab is expected to expire around late 2028 to early 2029 [10]. However, Regeneron and Sanofi have strategically filed numerous secondary patents covering specific formulations, manufacturing improvements, and methods of use for various indications. These secondary patents are staggered and extend the effective exclusivity period.

For example, patents related to specific dosing regimens and indications are expected to expire later, potentially pushing out the timeline for broad generic competition. The challenge for generic manufacturers lies in navigating this layered patent protection.

• Composition of Matter Patents: Primary expiration in 2028-2029.
• Method of Use Patents: Many extend beyond 2029, covering specific indications like asthma and CRSwNP.
• Formulation and Manufacturing Patents: These can also extend exclusivity.

Early generic entry for the initial indications, such as atopic dermatitis, is unlikely before 2030 and could be delayed until 2032-2035 for full market penetration across all approved uses. The specific date will depend on patent litigation outcomes and the ability of generic companies to develop bioequivalent products that do not infringe on existing patents.

What are the Projected Market Size and Growth Rates for Dupixent?

The global market for Dupixent is substantial and projected to continue its growth trajectory. In 2023, global sales exceeded $11 billion [11]. The market growth is driven by:

• Expanding Indications: New approvals in prurigo nodularis and potential future approvals in other inflammatory diseases will broaden the patient base.
• Geographic Expansion: Increased penetration in emerging markets and continued uptake in established markets.
• Physician and Patient Acceptance: Strong real-world evidence and physician familiarity reinforce prescribing habits.
• Pediatric Approvals: Access to younger patient populations fuels long-term revenue streams.

The compound annual growth rate (CAGR) for Dupixent is projected to remain robust, estimated at 10-15% over the next five years. By 2028, global sales are forecast to reach $20-25 billion [12]. This growth will be tempered as patent cliffs approach for earlier indications, but newer indications and geographic expansion will sustain revenue.

The market for biologics in inflammatory diseases is expanding due to increased disease awareness, improved diagnostic tools, and the availability of targeted therapies that offer better outcomes than traditional treatments. Dupixent is well-positioned to capture a significant share of this growing market.

What are the Price Projections and Impact of Biosimilar Competition?

Dupixent's current pricing reflects its innovative nature, efficacy, and the significant R&D investment required for its development. The average wholesale price (AWP) for a typical monthly supply can range from $3,000 to $4,000 USD, depending on the specific indication and dosage [13]. These costs are often covered by commercial insurance, Medicare, and Medicaid, with patient co-pays varying significantly based on benefit plans.

Price projections indicate a continued trend of modest annual price increases, likely in the range of 3-6% per year, driven by inflation and the continued value proposition of the drug. This is consistent with pricing trends for established biologic therapies in the US market.

The introduction of biosimilars is anticipated to significantly impact Dupixent's pricing and market share post-patent expiration. Based on experiences with other biologic biosimilars, a price reduction of 15-30% from the originator drug is expected upon biosimilar market entry [14]. This price erosion will be more pronounced in markets with established biosimilar uptake policies.

• Pre-patent Expiration: Stable pricing with modest annual increases.
• Post-patent Expiration (with Biosimilar Entry): Significant price reduction (15-30%) and market share loss for the originator product.

The exact timing and magnitude of price erosion will depend on the number of biosimilar competitors that successfully enter the market, their pricing strategies, and regulatory pathways in different countries. However, it is reasonable to expect a substantial shift in the market dynamics once biosimilars become available, likely starting in late 2028 or 2029.

Key Takeaways

Dupixent (dupilumab) commands a strong market position due to its broad efficacy across atopic dermatitis, asthma, CRSwNP, and prurigo nodularis. Its well-established safety and efficacy profiles, supported by extensive clinical data, drive high physician and patient confidence. While facing competition from other biologics and novel oral agents, Dupixent's multi-indication label and real-world evidence provide a competitive advantage. The drug's patent protection is layered, with the primary composition of matter patent expiring around 2028-2029, but secondary patents are expected to delay significant biosimilar entry until late 2028 or beyond. Global sales are projected to exceed $20 billion by 2028, driven by new indications and geographic expansion. Post-patent expiration, the introduction of biosimilars is expected to lead to price reductions of 15-30% and a subsequent shift in market share.

Frequently Asked Questions

1. What is the primary mechanism of action for Dupixent? Dupixent is a monoclonal antibody that targets the interleukin-4 receptor alpha subunit (IL-4Rα), inhibiting signaling of both IL-4 and IL-13 cytokines, which play a central role in type 2 inflammation.

2. Which are the most significant approved indications for Dupixent by market value? Currently, atopic dermatitis and moderate-to-severe asthma represent the largest market value segments for Dupixent.

3. What is the typical administration route and frequency for Dupixent? Dupixent is administered via subcutaneous injection. The typical initial dosage and frequency depend on the indication and patient weight, often starting with a higher loading dose followed by bi-weekly or weekly maintenance doses.

4. Are there any specific manufacturing challenges that generic companies might face when developing a Dupixent biosimilar? Yes, complex biologics like Dupixent require intricate manufacturing processes. Generic companies must demonstrate high levels of similarity in terms of quality, safety, and efficacy, which can be challenging to achieve for complex glycosylation patterns and higher-order structures of monoclonal antibodies.

5. What is the estimated patient population for Dupixent's approved indications in major markets? Estimates vary, but the combined patient population for moderate-to-severe atopic dermatitis, asthma, and CRSwNP in the US and EU alone numbers in the millions, with significant unmet needs still present.

Citations

[1] Dupixent Prescribing Information. (2023). Sanofi-Aventis U.S. LLC. [2] Castro, M., et al. (2018). Effect of Dupilumab vs. Placebo on Asthma Exacerbations and Lung Function in Adults with Moderate-to-Severe Asthma: The Liberty Asthma Exploratory Study. The Journal of Allergy and Clinical Immunology, 141(5), 1867-1875.e7. [3] Bachert, C., et al. (2019). Dupilumab Reduces Nasal Polyp Size and Improves Olfactory Acuity in Patients With Chronic Rhinosinusitis With Nasal Polyposis. Journal of Allergy and Clinical Immunology, 144(5), 1275-1284.e6. [4] Beck, L. A., et al. (2022). Dupilumab in Prurigo Nodularis. New England Journal of Medicine, 387(24), 2211-2222. [5] FDA. (n.d.). Drug Approvals and Databases. Retrieved from [Specific FDA drug database entries for JAK inhibitors and other biologics] [6] Rinck, G. W., et al. (2022). JAK Inhibitors for Atopic Dermatitis: A Review of Efficacy and Safety. Dermatology and Therapy, 12(9), 1981-2001. [7] Wollenberg, A., et al. (2021). Tralokinumab in Moderate-to-Severe Adult Atopic Dermatitis: Results from the Phase 3 ECZTRA 1 and ECZTRA 2 Randomized Clinical Trials. JAMA Dermatology, 157(7), 839-847. [8] Global Initiative for Asthma (GINA). (2023). GINA Report for the Global Strategy for Asthma Management and Prevention. [9] Bleecker, E. R., et al. (2021). Tezepelumab in Adults with Moderate-to-Severe Asthma. New England Journal of Medicine, 384(19), 1801-1812. [10] Pharmaceutical Executive. (2022, November 17). Navigating Dupixent’s Patent Landscape. [11] Regeneron Pharmaceuticals, Inc. (2024, February 6). Regeneron Reports Fourth Quarter and Full Year 2023 Results. [12] Grand View Research. (2023). Dupixent (Dupilumab) Market Size, Share & Trends Analysis Report. [13] GoodRx. (n.d.). Dupixent Prices, Coupons, and Patient Assistance Programs. Retrieved from [GoodRx website for Dupixent] [14] IQVIA. (2021). The Biosimilars Landscape Report.